Drug intelligence / Profile preview

beta-glucans + saccharomyces cerevisiae

Development stage
Phase 3
Lead developer
AB Biotek HNH
Administration
Oral, Intravenous, Topical
01

Overview

Beta-glucans from Saccharomyces cerevisiae are polysaccharides derived from the cell wall of baker’s yeast. These compounds are primarily composed of β(1→3) and β(1→6) glycosidic linkages. They function as biologically active immunomodulators and antioxidants. Mechanistically, they stimulate innate immune responses by binding to pattern recognition receptors such as Dectin‑1/CR3 (complement receptor 3), TLR4 (Toll-like receptor 4), and MMR (macrophage mannose receptor), activating downstream signaling pathways including Raf‑1, Syk, and PI3K[6][9][10]. This leads to enhanced phagocytosis and cytokine production by monocytes/macrophages and natural killer cells. Beta-glucans from S. cerevisiae have demonstrated efficacy in preclinical models for reducing tumor growth via trained immunity mechanisms[4][6][9], antioxidant effects through Nrf2/HO‑1 pathway activation[10], wound healing promotion[2][7], modulation of gut microbiota in inflammatory bowel disease[7], cholesterol reduction[5], glycemic control improvement[3], and potential adjuvant use in cancer immunotherapy or vaccine delivery systems[4]. They are widely used as dietary supplements for cardiovascular health support and immune enhancement.

Brand names
Qingke β-glucan
Other names
Yeast dextran(1-3),(1-6)-β-D-glucan
02

Targets

αMβ2 (Integrin αMβ2)CLEC7A (Dectin-1)MRC1 (Mannose Receptor C-type 1)TLR4 (Toll-like receptor 4)

Beyond the preview

Go deeper on beta-glucans + saccharomyces cerevisiae.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on beta-glucans + saccharomyces cerevisiae.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call